Anti-methyl auristatin E antibody and application thereof
By developing high-affinity MMAE antibodies, the problem of insufficient detection signal of existing reagents for low-toxin-loaded antibody-coupled drugs is solved, and accurate concentration determination and pharmacokinetic evaluation of antibody-coupled drugs are achieved.
Patent Information
- Application Number
- CN202410639074.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-05-25
- Filing Date
- 2024-05-22
- Publication Date
- 2024-11-26
AI Technical Summary
The existing commercial MMAE antibody reagents have low affinity for MMAE and cannot effectively detect antibody-conjugated drugs with low toxin load, resulting in deviations in pharmacokinetic evaluation.
A high-affinity MMAE antibody has been developed, containing specific heavy and light chain variable region amino acid sequences, which can specifically bind MMAE to detect MMAE toxins in antibody-conjugated drugs, providing a more authentic and reliable drug auxiliaries. Dynamics evaluation data.
High detection signals for low toxin load antibody-coupled drugs are achieved, more accurate pharmacokinetic evaluation is provided, and can be effectively applied to the concentration determination and stability analysis of antibody-coupled drugs.
Smart Images

Figure BDA0004852764000000081 
Figure BDA0004852764000000091 
Figure BDA0004852764000000092
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This patent application claims the priority benefit of the Chinese invention patent application with application number CN202310599463.3 filed on May 25, 2023, the entire contents of which are hereby incorporated by reference. Technical Field
[0003] The present invention relates to the field of biomedicine technology, and in particular to an anti-monomethylauristatin E (MMAE) monoclonal antibody and an application thereof. Background Art
[0004] Antibody-drug conjugate (ADC) is a special type of anti-tumor drug composed of an antibody or antibody-like ligand, a small molecule toxic drug, and a linker that couples the two. It uses the specific recognition ability of antibodies or antibody-like ligands for target cell surface antigens (such as specific antigens on the surface of tumor cells) to accurately deliver small molecule toxic drugs to target cells, thereby killing target cells while avoiding damage to normal cells. It has been considered to be one of the most promising anti-tumor drugs.
[0005] Monomethyl auristatin E (MMAE) is an antimitotic agent that can inhibit cell division by blocking the polymerization of tubulin. MMAE has been widely used as a small molecule toxic drug component of antibody-drug conjugates and used to treat various types of cancer. It is the most common toxic drug among ADC drugs currently under development.
[0006] In order to study the pharmacokinetics of antibody-drug conjugates with MMAE as the toxin part, many MMAE-specific reagents have been developed. However, the commercial MMAE antibody reagents currently sold on the market generally have low affinity for MMAE, especially unable to detect antibody-drug conjugates with low MMAE toxin load, resulting in deviations in the pharmacokinetic evaluation of antibody-drug conjugates.
[0007] Therefore, it is necessary to provide a high-affinity MMAE antibody reagent, which can provide a high detection signal for low-toxin-load antibody-drug conjugates, so that the pharmacokinetic evaluation data provided by the reagent will be more real and reliable. Summary of the invention
[0008] In order to solve the problem of quantitative detection of antibody-drug conjugates, especially the problem of low detection results for antibody-drug conjugates with low MMAE toxin loading, the present invention provides an anti-MMAE mouse monoclonal antibody with high affinity for MMAE, and successfully applies it to the concentration determination of antibody-drug conjugates with MMAE as the toxin part.
[0009] The present invention provides the following technical solutions.
[0010] In one aspect, the present invention provides an anti-monomethyl auristatin E (MMAE) antibody or a fragment thereof, wherein the anti-MMAE antibody or a fragment thereof can specifically bind to MMAE, such as MMAE conjugated as a toxin moiety in an antibody-drug conjugate.
[0011] Specifically, the anti-MMAE antibody or fragment thereof provided by the present invention comprises heavy chain complementary determining regions H-CDR1, H-CDR2 and H-CDR3 and light chain complementary determining regions L-CDR1, L-CDR2 and L-CDR3, wherein the complementary determining regions are derived from the following amino acid sequence combinations:
[0012] (1) the amino acid sequence shown in SEQ ID NO. 2; and the amino acid sequence shown in SEQ ID NO. 7; or
[0013] (2) the amino acid sequence shown in SEQ ID NO.12; and the amino acid sequence shown in SEQ ID NO.17.
[0014] The amino acid sequences in the above items are respectively the amino acid sequences of the heavy chain variable region and the light chain variable region of the specific anti-MMAE mouse antibody provided by the present invention; see the embodiment of the present invention. Using the definition tools of the complementary determining regions in the heavy chain or light chain of antibodies known or conventional in the art, those skilled in the art can easily determine the heavy chain CDRs and light chain CDRs contained when the two are combined to form an antibody. For example, in Example 2 of the present invention, the positions of the amino acid sequences of each CDR in the variable region when defining CDRs according to the KABAT scheme are provided. Heavy chain CDRs and light chain CDRs combinations can be obtained according to the definition tools known or conventional in the art, and antibodies or fragments thereof containing each CDR combination in these heavy chain CDRs and light chain CDRs combinations are within the scope of protection of the present invention.
[0015] Further, the anti-MMAE antibody or fragment thereof provided by the present invention comprises the following combination of heavy chain CDRs and light chain CDRs (H-CDR1, H-CDR2, H-CDR3; and, L-CDR1, L-CDR2, L-CDR3):
[0016] (1) the H-CDR1 comprises the amino acid sequence shown in SEQ ID NO.3 (DYTMH), the H-CDR2 comprises the amino acid sequence shown in SEQ ID NO.4 (GIYPNNGGTAYNQKFKG), and the H-CDR3 comprises the amino acid sequence shown in SEQ ID NO.5 (SYYGNYERFAY); and the L-CDR1 comprises the amino acid sequence shown in SEQ ID NO.8 (RSSQSLVHSNGNTYLH), the L-CDR2 comprises the amino acid sequence shown in SEQ ID NO.9 (KVSNRFS), and the L-CDR3 comprises the amino acid sequence shown in SEQ ID NO.10 (SQSTHVPLT); or
[0017] (2) the H-CDR1 comprises the amino acid sequence (DYYMF) shown in SEQ ID NO.13, the H-CDR2 comprises the amino acid sequence (YISNGGGRTYYPDTLKG) shown in SEQ ID NO.14, and the H-CDR3 comprises the amino acid sequence (QGNWDGDYYAIDY) shown in SEQ ID NO.15; and the L-CDR1 comprises the amino acid sequence (RSSQSLVYTNGNTYLH) shown in SEQ ID NO.18, the L-CDR2 comprises the amino acid sequence (KVSNRFS) shown in SEQ ID NO.19, and the L-CDR3 comprises the amino acid sequence (SQTTHIPLT) shown in SEQ ID NO.20.
[0018] Preferably, the anti-MMAE antibody or fragment thereof provided by the present invention comprises a heavy chain variable region (VH) and a light chain variable region (VL), both of which include the above-mentioned CDRs and a framework region (FR) therebetween, and the arrangement of each region is FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4.
[0019] Further, in the anti-MMAE antibody or fragment thereof provided by the present invention, the heavy chain variable region comprises the amino acid sequence shown in SEQ ID NO.2; the light chain variable region comprises the amino acid sequence shown in SEQ ID NO.7. Alternatively, in the anti-MMAE antibody or fragment thereof provided by the present invention, the heavy chain variable region comprises the amino acid sequence shown in SEQ ID NO.12; the light chain variable region comprises the amino acid sequence shown in SEQ ID NO.17.
[0020] In general, the present invention provides an anti-MMAE antibody, which is any form of anti-MMAE mouse antibody, chimeric antibody, partially or fully humanized antibody. In addition, the present invention provides a fragment of an anti-MMAE antibody, which is any fragment of the anti-MMAE antibody that retains high affinity and / or specific binding ability to MMAE. For example, the anti-MMAE antibody or its fragment provided by the present invention is a monoclonal antibody or scFv, BsFv, dsFv, (dsFv) 2, Fab, Fab', F(ab') 2 or Fv form. Preferably, the anti-MMAE antibody or its fragment may also include a constant region, preferably a heavy chain constant region (CH) and / or a light chain constant region (CL) of human or mouse origin. Preferably, the anti-MMAE antibody or its fragment comprises a heavy chain constant region and / or a κ or λ type light chain constant region selected from IgG, IgA, IgM, IgD or IgE.
[0021] According to a specific embodiment of the present invention, the anti-MAEE antibody provided by the present invention is a mouse monoclonal antibody, specifically:
[0022] (1) Mouse anti-S-49-8: the heavy chain comprises the amino acid sequence shown in SEQ ID NO.1, and the light chain comprises the amino acid sequence shown in SEQ ID NO.6; or
[0023] (2) Mouse anti-S-60-6: The heavy chain comprises the amino acid sequence shown in SEQ ID NO.11, and the light chain comprises the amino acid sequence shown in SEQ ID NO.16.
[0024] On the other hand, the present invention provides a nucleic acid molecule comprising a nucleotide sequence, which encodes the anti-MMAE antibody or fragment thereof described in the present invention, or encodes the heavy chain CDRs, light chain CDRs, heavy chain variable region, light chain variable region, heavy chain or light chain contained in the anti-MMAE antibody or fragment thereof described in the present invention.
[0025] In another aspect, the present invention provides a vector comprising the nucleic acid molecule. The vector may be a eukaryotic expression vector or a prokaryotic expression vector.
[0026] The vector or nucleic acid molecule of the present invention can be used to transform or transfect a host cell or enter a host cell in any manner for purposes such as preserving or expressing the anti-idiotypic antibody. Therefore, on the other hand, the present invention provides a host cell, the host cell comprising the nucleic acid molecule and / or vector of the present invention, or the host cell is transformed or transfected by the nucleic acid molecule and / or vector of the present invention. The host cell can be eukaryotic, such as a mammalian cell; or the host cell is prokaryotic, such as a bacterial cell.
[0027] Based on the disclosure of the present invention, the anti-MMAE antibodies or fragments thereof, nucleic acid molecules, vectors and / or host cells provided by the present invention can be obtained by using any conventional technical method known in the art.
[0028] Based on the high affinity and / or specific binding ability to MMAE, the anti-MMAE antibody or fragment thereof provided by the present invention can detect the concentration of the antibody-drug conjugate by specifically binding to the MMAE conjugated in the antibody-drug conjugate in the sample, and can be used to evaluate the stability, pharmacokinetics, toxicokinetics and other characteristics of the antibody-drug conjugate. In the context of the present invention, the terms "concentration", "content", "level", "presence" and the like are used interchangeably.
[0029] Therefore, in another aspect, the present invention provides the use of the anti-MMAE antibody or its fragment in the preparation of a reagent for detecting an antibody-drug conjugate containing MMAE. The reagent can be used to detect the concentration, content, level or presence of the antibody-drug conjugate in any sample.
[0030] On the other hand, the present invention provides the use of the anti-MMAE antibody or its fragment in the preparation of a reagent for detecting a drug containing MMAE (e.g., an antibody-drug conjugate containing MMAE or a polypeptide-drug conjugate containing MMAE). The reagent can be used to detect the concentration, content, level or presence of the drug (e.g., antibody-drug conjugate or polypeptide-drug conjugate) in any sample.
[0031] In the context of the present invention, "a drug comprising MMAE" refers to a drug having MMAE as one of its components, wherein MMAE is directly or indirectly associated with other components of the drug, such as an antibody-drug conjugate comprising MMAE or a polypeptide-drug conjugate comprising MMAE, or MMAE and other components of the drug exist independently in the drug.
[0032] In the context of the present invention, "antibody-drug conjugates containing MMAE" refers to ADCs obtained by coupling MMAE or a small molecule toxin drug containing MMAE to an antibody or antibody-like ligand via a linker; the antibody or antibody-like ligand in the ADC may target different targets, such as different tumor-associated antigens. According to the present invention, the antibody or antibody-like ligand in the antibody-drug conjugate containing MMAE may target HER2, B7H3, HER3, CD19, CD20, CD22, CD30, CD33, CD37, CD45, CD56, CD66e, CD70, CD74, CD73, CD79b, CD138, CD147, CD223, EpCAM, mucin 1 (Mucin1), STEAP1, GPNMB, FGF2, FOLR1, EGFR, EGFRvIII, tissue factor (Tissuefactor), c-MET, FGFR, Nectin4, AGS-16, Guanylyl cyclase C (Guanylyl cyclase C), antibodies or antibody-like ligands of mesothelin, SLC44A4, PSMA, EphA2, AGS-5, GPC-3, c-KIT, RoR1, PD-L1, CD27L, 5T4, Mucin16, NaPi2b, STEAP, SLITRK6, ETBR, BCMA, Trop-2, CEACAM5, SC-16, SLC39A6, Delta-like protein3, Claudin18.2, etc.
[0033] Preferably, the DAR value (the average value of the MMAE loading carried by the antibody) of the antibody-drug conjugate is in the range of 1-8, preferably 1-4.
[0034] Depending on the use environment, the reagent can be used for a detection method selected from the following: chemiluminescent immunoassay, enzyme-linked immunosorbent assay (ELISA), Western blotting, antibody microarray, immunoprecipitation and radioimmunoassay (RIA), etc. According to a specific embodiment of the present invention, the reagent is a detection reagent for ELISA.
[0035] Thus, in another aspect, the present invention provides a kit for detecting a drug containing MMAE (e.g., an antibody-drug conjugate containing MMAE or a polypeptide-drug conjugate containing MMAE), the kit comprising an anti-MMAE antibody or a fragment thereof provided by the present invention. The kit can be used to detect the concentration, content, level or presence of the drug (e.g., antibody-drug conjugate or polypeptide-drug conjugate) in any sample.
[0036] In another aspect, the present invention provides a kit for detecting an antibody-drug conjugate containing MMAE, the kit comprising an anti-MMAE antibody or a fragment thereof provided by the present invention. The kit can be used to detect the concentration, content, level or presence of the antibody-drug conjugate in any sample. Preferably, the DAR value (average value of the MMAE load carried by the antibody) of the antibody-drug conjugate is in the range of 1-8, preferably 1-4.
[0037] Depending on the use environment, the kit may be a kit for a detection method selected from the following: chemiluminescent immunoassay, enzyme-linked immunosorbent assay (ELISA), Western blotting, antibody microarray, immunoprecipitation and radioimmunoassay (RIA), etc. According to a specific embodiment of the present invention, the kit is an ELISA detection kit. And in particular, the ELISA detection kit includes the anti-MMAE antibody or fragment thereof of the present invention as a capture antibody.
[0038] Optionally, the kit also includes other reagents or tools required for detecting the antibody-drug conjugate, such as antibody diluent, washing solution, ELISA plate, color development solution, stop solution, etc.
[0039] In another aspect, the present invention provides a method for detecting a drug containing MMAE (e.g., an antibody-drug conjugate containing MMAE or a polypeptide-drug conjugate containing MMAE) in a sample, the method comprising the following steps:
[0040] (a) contacting the sample with the anti-MMAE antibody or fragment thereof provided by the present invention under conditions sufficient to allow the anti-MMAE antibody or fragment thereof provided by the present invention to form an immune complex with the drug (e.g., antibody-drug conjugate or polypeptide-drug conjugate);
[0041] (b) detecting the presence of the immune complex, wherein the presence of the immune complex indicates the presence of the drug (eg, antibody-drug conjugate or polypeptide-drug conjugate) in the sample.
[0042] In another aspect, the present invention provides a method for detecting an antibody-drug conjugate containing MMAE in a sample, the method comprising the following steps:
[0043] (a) contacting the sample with the anti-MMAE antibody or fragment thereof provided by the present invention under conditions sufficient to form an immune complex between the anti-MMAE antibody or fragment thereof provided by the present invention and the antibody-drug conjugate;
[0044] (b) detecting the presence of the immune complex, wherein the presence of the immune complex indicates the presence of the antibody-drug conjugate in the sample.
[0045] Preferably, the DAR value (the average value of the MMAE loading carried by the antibody) of the antibody-drug conjugate is in the range of 1-8, preferably 1-4.
[0046] The sample may be any solution or fluid that may contain the antibody-drug conjugate, such as a biological sample isolated from a subject to which the antibody-drug conjugate may have been administered. The subject may be a mammal, preferably a primate or a rodent, more preferably a human. Preferably, the sample is whole blood, plasma or serum.
[0047] Preferably, in step (a), the anti-MMAE antibody or fragment thereof is directly or indirectly immobilized on a solid support.
[0048] Preferably, in step (b), detecting the presence of the immune complex is achieved as follows:
[0049] i. via a detectable label directly or indirectly linked to the anti-MMAE antibody or fragment thereof; or
[0050] ii. It is achieved by binding to other reagents of the anti-MMAE antibody or fragment thereof or the antibody-drug conjugate, wherein the other reagents are directly or indirectly linked to a detectable label; for example, the other reagents can be a second antibody (secondary antibody) against the anti-MMAE antibody or fragment thereof or the antibody-drug conjugate.
[0051] Depending on the detection method, the detectable marker is, for example, a radioactive label, a luminescent label, a chromogenic label, a hapten, a metal or an enzyme label. The hapten can be digoxin or biotin. The enzyme label can be horseradish peroxidase. The metal can be colloidal gold. According to a specific embodiment of the present invention, the method is an enzyme-linked immunosorbent assay (ELISA), such as direct or indirect ELISA.
[0052] The present invention screened a large number of candidate antibody molecules through the classic mouse monoclonal antibody hybridoma preparation technology, and finally screened several MMAE monoclonal antibodies with high affinity and specific binding ability to MMAE. Experiments have shown that the anti-MMAE mouse monoclonal antibody provided by the present invention can specifically recognize MMAE, especially MMAE in antibody-coupled drugs with MMAE as a small molecule toxin drug component, and can also detect antibody-coupled drugs with low MMAE toxin load. The anti-MMAE mouse monoclonal antibody provided by the present invention can be applied to the research and development of antibody-coupled drugs with MMAE as a toxin, for example, in the plasma stability analysis, pharmacokinetic analysis, toxicokinetic analysis, etc. of the antibody-coupled drugs. BRIEF DESCRIPTION OF THE DRAWINGS
[0053] The embodiments of the present invention are described in detail below with reference to the accompanying drawings, wherein:
[0054] Figure 1 Concentration-absorbance curves of various ADCs using MMAE as toxin are shown.
[0055] Figure 2 The standard curve of ADC detection with MMAE as toxin at different concentrations in plasma is shown. The results show that the standard curve has a high degree of fit and can be used for quantitative analysis of unknown samples.
[0056] Figure 3 The concentration-time curve of ADC with MMAE as toxin in plasma at different time points is shown. The results show that the stability of ADC with MMAE as toxin in plasma can be well detected using the MMAE antibody reagent of the present invention.
[0057] Figure 4 The curve of the change of ADC drug concentration in rat blood over time after a single dose of 5 mg / kg of ADC drug was given to rats is shown. The results show that the MMAE antibody reagent of the present invention can well detect the ADC drug concentration in rat blood, reflecting the in vivo metabolic behavior of the drug. DETAILED DESCRIPTION
[0058] The present invention is described below with reference to specific examples. It will be appreciated by those skilled in the art that these examples are only used to illustrate the present invention and are not intended to limit the scope of the present invention in any way.
[0059] The experimental methods in the following examples are conventional methods unless otherwise specified. The raw materials, reagents, etc. used in the following examples are commercially available products unless otherwise specified.
[0060] Example 1 Preparation of anti-MMAE antibodies
[0061] 1. Preparation of Immunogen BSA-MMAE
[0062] Bovine serum albumin (BSA) was dissolved in phosphate buffer, and MMAE with a linker (vcMMAE, purchased from Shanghai Haoyuan Pharmaceutical Technology Co., Ltd.) was dissolved in N,N-dimethylacetamide. The BSA solution and the vcMMAE solution were mixed and fully reacted at 25°C, and then the prepared BSA-vcMMAE buffer was replaced with a phosphate buffer.
[0063] 2. Mouse Immunization and Hybridoma Preparation
[0064] The obtained BSA-vcMMAE was used to immunize 5 Balb / c mice, each immunized 3 times, each cycle was 3 weeks. It was determined that the immunized mouse serum specifically bound to the corresponding immunogen, and the antiserum titer should be above 1:10,000.
[0065] Select 1-2 mice with the highest titer from the immunized mice, isolate spleen cells and fuse them with SP2 / 0 myeloma cells. Amplify and culture hybridoma cells, take the supernatant to detect ELISA titer and antibody subtype, and select cells that are positive for the corresponding antigen for multiple rounds of subcloning. In order to ensure the positive rate of the hybridoma cell line and the stable production of antibodies, 3-4 clones are performed, with an interval of 1-2 weeks between each clone. As shown in Table 1, the supernatant detection signal values of clones S-49-8 and S-60-6 are the strongest, the antibody titer is the highest, and 3-4 times are 100% positive clones. After the cells are expanded and cultured, ascites is prepared and purified to obtain anti-MMAE mouse monoclonal antibodies.
[0066] Table 1. ELISA method to detect the titer of anti-MMAE mouse monoclonal hybridoma supernatant
[0067]
[0068] Example 2 Sequence determination of anti-MMAE antibody
[0069] As above, hybridoma clone cells were obtained, RNA was extracted, and cDNA was obtained by reverse transcription. The heavy chain and light chain variable region genes in the mouse monoclonal antibody were obtained by PCR, and the antibody heavy chain and light chain variable region genes were sequenced. The sequencing results were analyzed by bioinformatics to eliminate non-functional antibody genes. The antibodies were named according to the hybridoma cell clones from which they were derived: S-49-8 and S-60-6. The amino acid sequences of the antibodies are as follows. The heavy chain and light chain constant regions are mouse IgG1 antibody sequences, the heavy chain and light chain variable regions are shown in italics and underlined, and the complementary determining region (CDR) sequences are further shown in bold, defined according to the KABAT naming system.
[0070] 1. S-49-8 antibody amino acid sequence
[0071] Heavy chain (HC):
[0072]
[0073] HC: SEQ ID NO.1;
[0074] VH: SEQ ID NO.2;
[0075] H-CDR1: SEQ ID NO.3; H-CDR2: SEQ ID NO.4; H-CDR3: SEQ ID NO.5 Light chain (LC):
[0076]
[0077] LC: SEQ ID NO.6;
[0078] VL: SEQ ID NO.7;
[0079] L-CDR1: SEQ ID NO.8; L-CDR2: SEQ ID NO.9; L-CDR3: SEQ ID NO.102. S-60-6 antibody amino acid sequence
[0080] Heavy chain (HC):
[0081]
[0082] HC: SEQ ID NO.11;
[0083] VH: SEQ ID NO.12;
[0084] H-CDR1: SEQ ID NO.13; H-CDR2: SEQ ID NO.14; H-CDR3: SEQ ID NO.15 Light chain (LC):
[0085]
[0086] LC: SEQ ID NO.16;
[0087] VL: SEQ ID NO.17;
[0088] L-CDR1: SEQ ID NO.18; L-CDR2: SEQ ID NO.19; L-CDR3: SEQ ID NO.20 Example 3 Application of MMAE antibody reagents in nonclinical and clinical drug analysis
[0089] 1. Combination of MMAE antibody reagents with various forms of MMAE-conjugated ADC drugs
[0090] Enzyme-linked immunosorbent assay (ELISA) is often used in clinical and non-clinical pharmacokinetic studies of ADCs. Small molecule antibodies, such as MMAE antibody reagents, are often used as capture antibodies in ELISA to capture ADCs with at least one toxin. This example takes ADCs with four MMAE toxins as examples to investigate whether the MMAE antibody in the present invention can be used as an MMAE antibody reagent to be widely used in the analysis of various ADC drugs.
[0091] ADC1 used in the following experiments is an ADC targeting Nectin-4, MMAE is connected to the antibody by site-specific coupling, and the drug-antibody ratio is 4.0; ADC2 is an ADC targeting FOLR1, MMAE is connected to the antibody by site-specific coupling, and the drug-antibody ratio is 4.0; ADC3 is an ADC targeting HER2, MMAE is connected to the antibody by random coupling, and the drug-antibody ratio is 3.8; ADC4 is an ADC targeting Nectin-4, MMAE is connected to the antibody by random coupling, and the drug-antibody ratio is 3.7. The specific ELISA detection method is as follows.
[0092] ① Coating and blocking: Dilute MMAE antibody (S-49-8 and S-60-6) to 2μg / ml with coating solution, and coat overnight at 2-8℃. Pat the ELISA plate dry, rinse the ELISA plate 3 times with washing buffer, pat dry, add 3% BSA / PBST, and incubate at room temperature for 2h. Pat the blocked ELISA plate dry, and rinse the ELISA plate 3 times with washing buffer.
[0093] ② Standard curve sample and quality control dilution: Four different MMAE-conjugated ADC drugs were diluted with 1% BSA / PBST to 100ng / ml (ULOQ), 50ng / ml, 25ng / ml, 12.5ng / ml, 6.25ng / ml, 3.12ng / ml, 1.56ng / ml (LLOQ) and 0.78ng / ml (anchor point). The blank control (0ng / ml) was used as part of the standard curve but was not involved in the standard curve fitting. Five concentration quality controls were prepared with 1% BSA / PBST for the four MMAE-conjugated ADCs, with the concentrations of 100ng / ml (ULOQ, upper limit of quantification), 80ng / ml (HQC, high concentration quality control), 20ng / ml (MQC, medium concentration quality control), 4.0ng / ml (LQC, low concentration quality control), and 1.56ng / ml (LLOQ, lower limit of quantification).
[0094] ③ Sample addition: Add the above standard curve samples and quality control samples to the ELISA plate and incubate at room temperature for 2 hours.
[0095] ④ Add detection antibody: After incubation, pat the ELISA plate dry and rinse the ELISA plate 6 times with washing buffer. Dilute goat anti-human IgG-HRP with 1% BSA / PBST at 1:40000 and add to the ELISA plate, incubate at room temperature for 1 hour.
[0096] ⑤ Color development: After incubation, pat the ELISA plate dry and rinse the ELISA plate 6 times with washing buffer. Add TMB substrate and incubate at room temperature in the dark for about 10 minutes. Add 1M H3PO4 to terminate the reaction.
[0097] ⑥ Plate reading: After the color development reaction is terminated, use 650nm as the reference wavelength and read the OD value at 450nm.
[0098] The results are shown in Tables 2 to 5 and Figure 1 As shown, the two MMAE antibody reagents showed good concentration-absorbance linearity in the analysis of four ADC drugs, and the precision and accuracy of the quality control samples were good.
[0099] Table 2. MMAE coupled ADC1 measurement results
[0100]
[0101] Table 3. MMAE coupled ADC2 measurement results
[0102]
[0103]
[0104] Table 4. MMAE coupled ADC3 measurement results
[0105]
[0106]
[0107] Table 5. MMAE coupled ADC4 measurement results
[0108]
[0109]
[0110] The above results show that no matter what antigen the antibody targets, no matter whether MMAE is connected to the antibody by site-specific coupling or random coupling, the antibody provided by the present invention as an MMAE antibody reagent can accurately detect these ADCs.
[0111] 2. Detection ability of MMAE antibody reagent for ADCs with different MMAE loadings
[0112] After the antibody-drug conjugate is administered to humans or animals, a mixture of ADCs with various drug-antibody ratios (DAR values) will be produced through in vivo circulation and drug metabolism. This example investigates the detection capabilities of the antibodies S-49-8 and S-60-6 of the present invention and two commercially available MMAE mouse monoclonal antibodies as MMAE antibody reagents for ADCs with different DAR values. The specific detection method is as follows:
[0113] ① Coating and blocking: The two MMAE antibody reagents (S-49-8 and S-60-6) of the present invention and two commercially available MMAE mouse monoclonal antibodies (commercially available antibody A and commercially available antibody B, antibody A: purchased from Beijing Tiancheng Biotechnology Co., Ltd., item number 05-0096B; antibody B: Beijing Biopsies Biotechnology Co., Ltd., item number MME-M5252) were diluted to 2 μg / ml with coating solution and coated overnight at 2-8°C. The ELISA plate was patted dry, rinsed with washing buffer 3 times, patted dry, added with 3% BSA / PBST, and incubated at room temperature for 2 hours. The blocked ELISA plate was patted dry, and the ELISA plate was rinsed with washing buffer 3 times.
[0114] ② Dilution of standard curve samples and samples with different DAR values: MMAE-coupled ADC (DAR=4) was diluted as a standard curve sample and diluted to 100 ng / ml (ULOQ), 50 ng / ml, 25 ng / ml, 12.5 ng / ml, 6.25 ng / ml, 3.12 ng / ml, 1.56 ng / ml (LLOQ) and 0.78 ng / ml (anchor point) with 1% BSA / PBST. The blank control (0 ng / mL) was used as part of the standard curve but was not involved in the standard curve fitting. The MMAE-coupled ADCs with four different DAR values as described above (DAR=1, 2, 3, 4) and the corresponding naked antibodies (antibodies not coupled to MMAE, DAR=0) were diluted to three concentrations with 1% BSA / PBST: 80 ng / ml, 20 ng / ml and 4.0 ng / ml.
[0115] ③ Sample addition: Add the diluted standard curve samples and test samples to the ELISA plate respectively and incubate at room temperature for 2 hours.
[0116] ④ Add detection antibody: After incubation, pat the ELISA plate dry and rinse the ELISA plate 6 times with washing buffer. Dilute goat anti-human IgG-HRP with 1% BSA / PBST at 1:40000 and add to the ELISA plate, incubate at room temperature for 1 hour.
[0117] ⑤ Color development: After incubation, pat the ELISA plate dry and rinse the ELISA plate 6 times with washing buffer. Add TMB substrate and incubate at room temperature in the dark for about 10 minutes. Add 1M H3PO4 to terminate the reaction.
[0118] ⑥ Plate reading: After the color development reaction is terminated, use 650nm as the reference wavelength and read the OD value at 450nm.
[0119] The results are shown in Table 6. Compared with the two commercially available MMAE antibody reagents, the MMAE antibodies S-49-8 and S-60-6 of the present invention have higher small molecule binding ability, especially for ADCs with DAR values of 1 and 2. The two MMAE antibodies of the present invention have higher accuracy as MMAE antibody reagents. For naked antibodies, because they are not coupled with MMAE, they cannot be captured by antibodies and therefore cannot be detected.
[0120] Table 6. Detection results of various MMAE antibody reagents on ADCs with different DAR values
[0121]
[0122] 3. Application of MMAE antibody reagent in the study of plasma stability of MMAE-conjugated ADC
[0123] Investigating the stability of ADC drugs in plasma in vitro can be used to predict whether the drug can remain stable in the blood after entering the body, which is crucial for evaluating the drug's drugability and developability. ADCs may break linkers in plasma by chemical or biological enzyme catalysis, releasing small molecule toxins and forming a series of ADCs with different DAR values. In order to determine the concentration of ADCs connected to at least one MMAE molecule in plasma, a high-affinity MMAE antibody reagent is needed to capture ADCs of different DAR values indiscriminately and accurately determine their concentrations.
[0124] The in vitro plasma stability of ADC drugs was investigated as follows: normal monkey mixed plasma was filtered with a 0.22 μm filter membrane to remove bacteria and other microorganisms, and used to prepare 50 μg / ml (HPC) and 5 μg / ml (LPC) MMAE-coupled ADC samples. The samples were placed at 37°C and sampled at 0, 6h, 12h, 1 day, 3 days, 5 days, 7 days, 10 days, and 14 days, and the ADC concentration was determined by ELISA as follows:
[0125] ① Coating and blocking: Dilute the MMAE antibody reagent S-49-8 to 2μg / ml with coating solution and coat overnight at 2-8℃. Pat the ELISA plate dry, rinse the ELISA plate 3 times with washing buffer and pat dry, add 3% BSA / PBST, and incubate at room temperature for 2h. Pat the blocked ELISA plate dry, and rinse the ELISA plate 3 times with washing buffer.
[0126] ②Sample preparation:
[0127] Standard curve sample dilution: MMAE-conjugated ADC was diluted to 100 ng / ml with 2% mixed monkey plasma as the starting concentration, and 2-fold serial dilution was performed for a total of 8 points, with 2% mixed monkey plasma as the 0 point.
[0128] Quality control sample dilution: MMAE-conjugated ADC was diluted with 2% mixed monkey plasma as quality control samples, with concentrations of ULOQ: 100 ng / ml, HQC: 80 ng / ml, MQC: 20 ng / ml, LQC: 4 ng / ml, and LLOQ: 1.56 ng / ml.
[0129] Dilution of the test samples: HPC and LPC stability samples that have been placed for different periods of time were first diluted 50 times with 1% BSA / PBST, and then further diluted to 20 ng / ml with 2% mixed monkey plasma.
[0130] ③ Sample addition: Add the diluted samples to the ELISA plate and incubate at room temperature for 2 hours.
[0131] ④ Add detection antibody: After incubation, pat the ELISA plate dry and rinse the ELISA plate 6 times with washing buffer. Dilute goat anti-human IgG-HRP with 1% BSA / PBST at 1:40000 and add to the ELISA plate, incubate at room temperature for 1 hour.
[0132] ⑤ Color development: After incubation, pat the ELISA plate dry and rinse the ELISA plate 6 times with washing buffer. Add TMB substrate and incubate at room temperature in the dark for about 10 minutes, then add 1M H3PO4 to terminate the reaction.
[0133] ⑥ Plate reading: After the color development reaction is terminated, use 650nm as the reference wavelength and read the OD value at 450nm.
[0134] The results are shown in Table 7 and Figure 2 , Figure 3 As shown, the concentration-absorbance of MMAE-coupled ADC has good linearity. As the storage time of ADC drugs in plasma increases, the ADC concentration gradually decreases, indicating that the antibody of the present invention can be effectively used to evaluate the plasma stability of ADC drugs.
[0135] Table 7. Standard curve data of drug concentration-absorbance change of MMAE-conjugated ADC
[0136]
[0137]
[0138] 4. Application of MMAE antibody reagent in in vivo pharmacokinetic analysis of MMAE-conjugated ADC in rats
[0139] The MMAE-coupled ADC was intravenously injected into rats at a dose of 5 mg / kg, and a total of 8 rats (half male and half female) were administered in parallel. 200 μl of blood was collected from the tail vein at 5 min, 1 h, 8 h, 24 h, 48 h, 96 h and 168 h after administration. After the blood was allowed to stand for 30 min, the serum was separated by centrifugation at 1000 rpm for 30 min, and then the ADC drug concentration in the serum was determined by ELISA. The specific determination method is based on the MMAE antibody in the present invention, and the method is as follows:
[0140] ① Coating and blocking: Dilute the MMAE antibody reagent S-49-8 to 2μg / mL with coating solution, add 100μl / well to the ELISA plate, and incubate at 2-8℃ overnight. Pat the ELISA plate dry and rinse the ELISA plate 3 times with 300μl / well PBST. Pat the ELISA plate dry, add 200μl / well 3% BSA / PBST, and incubate at 37±1℃, 450rpm shaking for 1h±5min. Pat the blocked ELISA plate dry and rinse the ELISA plate 3 times with 200μl / well washing buffer.
[0141] ②Sample preparation:
[0142] Standard curve sample dilution: MMAE-coupled ADC (ADC1 in Example 3) was diluted with 1% mixed normal rat serum to 8 concentration points of 25, 20, 12.5, 6.25, 3.13, 1.56, 1, and 0.391 ng / ml, respectively, and 1% mixed normal rat serum was used as the matrix blank.
[0143] Quality control sample dilution: MMAE-conjugated ADC was diluted with 1% mixed normal rat serum as quality control samples, with concentrations of HQC: 18.8 ng / ml, MQC: 10 ng / ml, and LQC: 2.5 ng / ml.
[0144] Sample dilution: The collected rat serum samples were diluted 100 times with 1% BSA / PBST for detection. If the concentration of the sample to be tested exceeds 25 ng / ml, it was further diluted with 1% mixed rat serum until it fell into the detection range.
[0145] ③ Sample addition: Add the diluted standard curve samples, matrix blanks, quality control samples and blood samples to be tested into the ELISA plate at 100 μl / well, set up duplicate wells, seal the plate with a sealing film, and incubate at 37±1℃ and 450rpm for 3.5h±5min.
[0146] ④ Add biotin-labeled nectin-4: Pat the ELISA plate dry, and rinse the ELISA plate 3 times with 300 μl / well of washing buffer. Dilute biotin-labeled nectin-4 (recombinant nectin-4 is prepared by mammalian cell expression and purification, and then labeled with a commercial biotin labeling kit to obtain biotin-labeled nectin-4) with 1% BSA / PBST at 1:1000, add 100 μl / well to the ELISA plate, seal the plate with a sealing film, and incubate at 37±1°C, 450rpm, and shake for 1h±5min.
[0147] ⑤ Add Streptavidin-HRP: Pat the ELISA plate dry, wash the ELISA plate 3 times with 300μl / well of washing buffer. Dilute SA-HRP with 1% BSA / PBST at 1:5000, add 100μl / well to the ELISA plate, seal the plate with a sealing film, and incubate at 37±1℃, 450rpm, shaking for 1h±5min.
[0148] ⑥ Color development: Pat the ELISA plate dry and rinse the ELISA plate 3 times with 300μl / well of washing buffer. Add 100μl / well of TMB substrate that has been equilibrated to room temperature to the ELISA plate and incubate at 37±1℃ and 450rpm for 15±5min. Add 100μl / well of 1M H3PO4 to terminate the reaction.
[0149] ⑦ Plate reading: After terminating the color development reaction, use 650nm as the reference wavelength and read the OD value at 450nm.
[0150] The results are shown in Table 8 and Figure 4 As shown, the accuracy of all quality control samples in this test was within the range of 80.0-120.0%, meeting the methodological requirements. The concentration-time curve of the MMAE-coupled ADC drug in rats after administration showed a normal drug pharmacokinetic curve, indicating that the MMAE antibody of the present invention can well detect the concentration of the MMAE-coupled ADC drug in the blood.
[0151] Table 8. Results of quality control sample testing for in vivo pharmacokinetic study of MMAE-conjugated ADC drugs in rats
[0152]
[0153] The above description of the specific embodiments of the present invention does not limit the present invention. Those skilled in the art may make various changes or modifications based on the present invention. As long as they do not depart from the spirit of the present invention, they should all fall within the scope of the claims attached to the present invention.
Claims
1. An anti-monomethyl auristatin E (MMAE) antibody or a fragment thereof, wherein the anti-MMAE antibody or a fragment thereof comprises heavy chain complementary determining regions H-CDR1, H-CDR2 and H-CDR3 and light chain complementary determining regions L-CDR1, L-CDR2 and L-CDR3, Features: (1) the H-CDR1 comprises the amino acid sequence shown in SEQ ID NO.3 (DYTMH), the H-CDR2 comprises the amino acid sequence shown in SEQ ID NO.4 (GIYPNNGGTAYNQKFKG), and the H-CDR3 comprises the amino acid sequence shown in SEQ ID NO.5 (SYYGNYERFAY); and the L-CDR1 comprises the amino acid sequence shown in SEQ ID NO.8 (RSSQSLVHSNGNTYLH), the L-CDR2 comprises the amino acid sequence shown in SEQ ID NO.9 (KVSNRFS), and the L-CDR3 comprises the amino acid sequence shown in SEQ ID NO.10 (SQSTHVPLT); or (2) the H-CDR1 comprises the amino acid sequence (DYYMF) shown in SEQ ID NO.13, the H-CDR2 comprises the amino acid sequence (YISNGGGRTYYPDTLKG) shown in SEQ ID NO.14, and the H-CDR3 comprises the amino acid sequence (QGNWDGDYYAIDY) shown in SEQ ID NO.15; and the L-CDR1 comprises the amino acid sequence (RSSQSLVYTNGNTYLH) shown in SEQ ID NO.18, the L-CDR2 comprises the amino acid sequence (KVSNRFS) shown in SEQ ID NO.19, and the L-CDR3 comprises the amino acid sequence (SQTTHIPLT) shown in SEQ ID NO.
20.
2. The anti-MMAE antibody or fragment thereof according to claim 1, It is characterized in that The anti-MMAE antibody or fragment thereof comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the heavy chain variable region comprises the amino acid sequence shown in SEQ ID NO.2, and the light chain variable region comprises the amino acid sequence shown in SEQ ID NO.7; or, the heavy chain variable region comprises the amino acid sequence shown in SEQ ID NO.12; and the light chain variable region comprises the amino acid sequence shown in SEQ ID NO.17; Preferably, the anti-MMAE antibody is a mouse antibody, a chimeric antibody, or a partially or fully humanized antibody against MMAE; or, the fragment is any fragment of the anti-MMAE antibody that retains high affinity and / or specific binding ability to MMAE; Preferably, the anti-MMAE antibody or fragment thereof is in the form of a monoclonal antibody or scFv, BsFv, dsFv, (dsFv)2, Fab, Fab', F(ab')2 or Fv.
3. The anti-MMAE antibody or fragment thereof according to claim 1 or 2, It is characterized in that The anti-MMAE antibody or fragment thereof may further comprise a constant region, preferably a heavy chain constant region (CH) and / or a light chain constant region (CL) of human or murine origin; Preferably, the anti-MMAE antibody or fragment thereof comprises a heavy chain constant region selected from IgG, IgA, IgM, IgD or IgE and / or a κ or λ type light chain constant region; Further preferably, the anti-MAEE antibody is the following mouse monoclonal antibody: (1) Mouse anti-S-49-8: the heavy chain comprises the amino acid sequence shown in SEQ ID NO.1, and the light chain comprises the amino acid sequence shown in SEQ ID NO.6; or (2) Mouse anti-S-60-6: The heavy chain comprises the amino acid sequence shown in SEQ ID NO.11, and the light chain comprises the amino acid sequence shown in SEQ ID NO.
16. 4 . A nucleic acid molecule comprising a nucleotide sequence encoding the anti-MMAE antibody or a fragment thereof according to any one of claims 1 to 3 . A vector comprising the nucleic acid molecule according to claim 4 .
6. A host cell comprising the nucleic acid molecule according to claim 4 and / or the vector according to claim 5, or transformed or transfected with the nucleic acid molecule according to claim 4 and / or the vector according to claim 5.
7. Use of the anti-MMAE antibody or fragment thereof according to any one of claims 1 to 3 in the preparation of a reagent for detecting a drug containing MMAE; Preferably, the drug comprising MMAE is selected from an antibody-drug conjugate comprising MMAE and a polypeptide-drug conjugate comprising MMAE; More preferably, the drug comprising MMAE is selected from antibody-drug conjugates comprising MMAE.
8. The use according to claim 7, It is characterized in that The reagent is used in a detection method selected from the group consisting of: chemiluminescent immunoassay, enzyme-linked immunosorbent assay (ELISA), Western blotting, antibody microarray, immunoprecipitation, and radioimmunoassay (RIA); Preferably, the reagent is a detection reagent for ELISA.
9. A kit for detecting a drug containing MMAE, the kit comprising the anti-MMAE antibody or fragment thereof according to any one of claims 1 to 3; Preferably, the drug comprising MMAE is selected from an antibody-drug conjugate comprising MMAE and a polypeptide-drug conjugate comprising MMAE; More preferably, the drug comprising MMAE is selected from antibody-drug conjugates comprising MMAE.
10. The kit according to claim 9, It is characterized in that The kit is a kit for a detection method selected from the group consisting of: chemiluminescent immunoassay, enzyme-linked immunosorbent assay (ELISA), Western blotting, antibody microarray, immunoprecipitation, and radioimmunoassay (RIA); Preferably, the kit is an ELISA detection kit; Further preferably, the kit comprises the anti-MMAE antibody or fragment thereof according to any one of claims 1 to 3 as a capture antibody for the antibody-drug conjugate; Preferably, the kit further comprises other reagents or tools required for detecting the antibody-drug conjugate, such as antibody diluent, washing solution, ELISA plate, color development solution, and stop solution.
11. A method for detecting a drug containing MMAE in a sample, the method comprising: The following steps are involved: (a) contacting a sample with the anti-MMAE antibody or fragment thereof according to any one of claims 1 to 3 under conditions sufficient for the anti-MMAE antibody or fragment thereof to form an immune complex with a drug comprising MMAE; (b) detecting the presence of the immune complex, wherein the presence of the immune complex indicates the presence of the drug in the sample; Preferably, the drug comprising MMAE is selected from an antibody-drug conjugate comprising MMAE and a polypeptide-drug conjugate comprising MMAE; More preferably, the drug comprising MMAE is selected from antibody-drug conjugates comprising MMAE.
12. The method according to claim 11, It is characterized in that In step (a), the anti-MMAE antibody or fragment thereof is directly or indirectly immobilized on a solid support; and / or In step (b), detecting the presence of the immune complex is achieved as follows: i. via a detectable label directly or indirectly linked to the anti-MMAE antibody or fragment thereof; or ii. via other agents that bind to the anti-MMAE antibody or fragment thereof or the antibody-drug conjugate, wherein the other agents are directly or indirectly linked to a detectable label.
